PUBLISHER: SkyQuest | PRODUCT CODE: 1463430
PUBLISHER: SkyQuest | PRODUCT CODE: 1463430
Global Blood Screening Market size was valued at USD 2.73 Billion in 2022 and is poised to grow from USD 2.96 Billion in 2023 to USD 5.69 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).
Automated molecular platforms for Blood Screening have become increasingly popular among leading industry players, driving market expansion. The growth of the Blood Screening market is fueled by several key factors including the escalating number of blood donations and donors, heightened awareness regarding the safety of donated blood, the surge in infectious diseases, and various governmental initiatives. This surge is further bolstered by the staggering volume of major surgeries conducted worldwide annually, surpassing 234 million according to the December 2021 article "Operative Risk". Additionally, blood transfusions are frequently administered in challenging childbirths to address issues like childhood acute anaemia, trauma, and congenital maternal blood abnormalities. Furthermore, data from the World Health Organization (WHO) Factsheet of June 2021 indicates that 118.5 million blood donations are made globally, with 40% originating from high-income countries, despite these countries only representing 16% of global blood donations. Notably, the proportion of donations relative to income levels highlights disparities, with high-income nations contributing 31.5%, upper-middle-income nations 15.9%, lower-middle-income nations 6.8%, and low-income nations 5.0%.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Blood Screening Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Blood Screening Market Segmental Analysis
Global Blood Screening Market is segmented on the basis of product type, end users and region. By product type, the market is segmented into reagents & kits, instruments, software. By end user, the market is segmented into hospitals & clinics, blood banks, diagnostic centers, and research laboratories. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Blood Screening Market
Healthcare professionals and patients are increasingly recognizing the potential dangers linked with blood transfusions, including the transmission of infectious diseases. Consequently, there is a rising need for blood screening products that guarantee the safety of both blood and blood-related products.
Restraints in the Global Blood Screening Market
The scarcity of phlebotomists, laboratory technicians, and other skilled workers in the industry could impede the widespread adoption of blood screening products. Healthcare institutions and blood banks may encounter difficulties in finding qualified personnel to operate the equipment and conduct tests, potentially limiting their ability to implement comprehensive blood screening programs.
Market Trends of the Global Blood Screening Market
The increasing demand for plasma-derived products like immunoglobulins and clotting factors is fueling the need for advanced blood screening tools to guarantee the safety of these products. This upward trajectory is projected to persist as the utilization of plasma-derived products extends into emerging therapeutic domains.